Stockwinners Market Radar for June 08, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:31 EDT Mitek Systems names Frank Teruel as new CFO - Mitek Systems "announced the appointment of Susan Repo to its board of directors and Frank Teruel to its leadership team as CFO. Susan Repo, currently the chief financial officer at ICEYE, a New Space earth observation technology company enabling access to real-time imagery from space to empower better decision making in governmental and commercial industries from its own constellation of synthetic aperture radar satellites, will join Mitek's board of directors effective immediately. Additionally, Frank Teruel will be joining Mitek as CFO and senior vice president effective July 16, 2021. Teruel will succeed Jeff Davison, who announced his retirement earlier this year. Teruel was previously the chief operating officer of ADARA, a global leader in predictive consumer intelligence through its permissioned data and verified identity platform".

19:13 EDT Pfizer says FDA approves Prevnar - Pfizer announce that the U.S. Food and Drug Administration has approved PREVNAR 20 for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae serotypes in the vaccine in adults ages 18 years and older. Following today's FDA approval, the U.S. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices is expected to meet in October to discuss and update recommendations on the safe and appropriate use of pneumococcal vaccines in adults. "Today's approval of PREVNAR 20 marks a significant step forward in our ongoing fight to help address the burden of pneumococcal disease, including pneumonia in adults, and broadens global protection against more disease-causing serotypes than any other pneumococcal conjugate vaccines," said Kathrin U. Jansen, Ph.D., Senior Vice President and Head of Vaccine Research & Development, Pfizer. "With a single injection, PREVNAR 20 provides adults with strong and meaningful protection against serotypes responsible for the majority of circulating pneumococcal disease around the world."

18:25 EDT Activision Blizzard CEO: We have a maniacal focus on customers - In an interview on CNBC's Mad Money, Bobby Kotick said Activision Blizzard is very focused on its customers in order to bring them the best content possible. The games are more social now than previously, and that has made them more popular and engaging, he added. "I don't come to work for the compensation. It was very easy for me to take a pay cut," he said.

17:53 EDT 8x8 CEO buys 43K shares of common stock - In a regulatory filing, 8x8 disclosed that its CEO David Sipes bought 43K shares of common stock on June 7th in a total transaction size of $1.0M, boosting his stake by about 9%. Shares of 8x8 are up by over 4% at $24.97 after-hours.

17:48 EDT TSX accepts West Fraser Timber's notice to increase shares buyback program - The Toronto Stock Exchange, or TSX, has accepted a notice filed by the Company of its intention to amend its current normal course issuer bid, or NCIB, to increase the authorization to purchase up to 9,582,470 of its Shares. This is an increase from the current NCIB authorization of 6,044,000 Shares. The amendments to the NCIB will become effective on June 11. The amended TSX notice authorizes the Company to purchase, during the 12-month period commencing February 17, 2021 and ending February 16, 2022, an additional 3,538,470 Shares of the Company representing in the aggregate 10% of the public float as at February 8, 2021. Under its current NCIB, as of June 7 the Company has purchased 3,859,039 Shares at an average price of $88.08 per Share, resulting in 5,723,431 Shares remaining available for purchase under the amended NCIB.

17:43 EDT ServisFirst to transfer stock listing to NYSE from Nasdaq - ServisFirst Bancshares, Inc. announced that it is transferring the listing of its common stock to the New York Stock Exchange from The NASDAQ Global Select Market. ServisFirst Bancshares's common stock will begin trading on the NYSE on June 21, 2021 under its current ticker symbol of 'SFBS'. ServisFirst Bancshares will continue to trade its common stock on NASDAQ until the close of the market on June 18, 2021. "ServisFirst Bancshares is pleased to join the NYSE, the global leader in listings with many of the world's most well-established companies, to continue to provide long term value for our customers and shareholders," stated Tom Broughton, ServisFirst Bancshares Chairman, President and CEO.

17:18 EDT Ovintiv CEO Doug Suttles to retire, Brendan McCracken to succeed - Ovintiv CEO Doug Suttles announced he will retire effective August 1. Ovintiv's board of directors has named Brendan McCracken as president and CEO and elected him to the board effective August 1. McCracken began his career with the company nearly 25 years ago. Most recently, he served Ovintiv as president. He has led a range of functions across the business, including strategy, external affairs and operations.

17:08 EDT TTEC Holdings director Frerichs sells $650K in shares - TTEC Holdings director Robert Frerichs disclosed in a filing tha the had sold 5,908 shares of company stock at $110 per share, on June 7 for a total transaction amount of $649,880.

17:06 EDT Casey's General Stores reports Q1 fuel same-store gallons sold up 6.4% - Reports Q1 Inside same-store sales up 12.8% and inside gross margin up 100bps at 39.9%.

16:40 EDT Pixel by LabCorp PCR test available in Walgreens, DoorDash and Instacart - Labcorp (LH) announced that Pixel by Labcorp COVID-19 PCR Test Home Collection Kits are now in 6,000 Walgreens (WBA) stores nationwide and through Walgreens collaborations with on-demand delivery services DoorDash (DASH) and Instacart. The newly expanded availability and delivery option advances Walgreens and Labcorp's efforts to increase COVID-19 testing access in communities across the U.S., especially in underserved areas. Customers will be able to purchase the Pixel by Labcorp COVID-19 PCR Test Home Collection Kit at the pharmacy counter without a prescription, or they can order it for delivery through DoorDash and Instacart.

16:31 EDT Sonnet BioTherapeutics issues U.S. patent for platform technology - The company states: "Sonnet BioTherapeutics announced that the United States Patent and Trademark Office has issued U.S. Patent No. 11,028,166 entitled, "Albumin Domain Fusion Proteins". The patent covers Sonnet's Fully Human Albumin Binding technology and includes therapeutic fusion proteins that utilize FHAB for tumor targeting and retention and provide extended pharmacokinetics (PK), and the patent carries a term effective until March 2039."

16:31 EDT Valaries announces floater contract award from Chevron - Valaris Limited (VAL) announced that it has been awarded a three-year contract with Chevron (CVX) in the U.S. Gulf of Mexico for drillship, VALARIS DS-18. The contract is expected to commence in the first quarter of 2022 in direct continuation of the current contract.

16:24 EDT Ouster signs strategic customer agreement with PARIFEX - Ouster announced that it has signed a strategic customer agreement with PARIFEX, a leading solution provider in project management for smart cities, to deploy Ouster's OS1 sensors on speed enforcement and data collection systems in France. Ouster has agreed be the exclusive lidar supplier for PARIFEX's ETU Project for the deployment and maintenance of mobile and fixed urban speed lidar enforcement systems in Northern France, with a potential supply demand of 500 sensors through 2025. PARIFEX offers the only approved lidar based system for speed measurement and control in the country.

16:21 EDT Worthington acquires Shiloh's U.S. BlankLight business for $105M - Worthington Industries announced the acquisition of certain assets of Shiloh Industries' U.S. BlankLight business, a leading provider of laser welded solutions that deliver material savings, weight and cost reductions and increased fuel efficiency to the mobility market. The acquisition expands the capacity and capabilities of Worthington's laser welded products joint venture, TWB Company, LLC, with the addition of three facilities and adds a blanking facility to its Steel Processing business. "The demand for tailor welded blanks and lightweighting technology is growing and the acquisition of these Shiloh assets allows us to support that growth while adding new capabilities," said Worthington Industries Executive Vice President and COO Geoff Gilmore. "Shiloh's BlankLight expertise in curvilinear and aluminum welded blanks adds to TWB's wide range of tailor welded products, creating more value and innovation for our customers." Gilmore added, "It also broadens our relationships with key automotive customers and expands the geographic reach of our Steel Processing business through an additional blanking operation." The transaction adds approximately 200 employees and four facilities located in Bowling Green, Ky., Canton, Mich. and two in Valley City, Ohio. TWB will operate the laser welded blank facilities in Ohio and Michigan. The Kentucky facility will operate under Worthington's Steel Processing business, expanding the blanking services currently provided from its Monroe, Ohio and Porter, Ind. facilities. The purchase price was approximately $105M, subject to closing adjustments. In calendar year 2020, the acquired assets generated

16:19 EDT Matterport's 3D technology selected by Jellis Craig Stonnington - Matterport, which has entered into a definitive agreement to enter into a business combination with Gores Holdings VI (GHVI), announced that one of Australia's leading realtors for sought-after Melbourne real estate, Jellis Craig Stonnington, is accelerating its use of Matterport 3D technology to power and differentiate its high-end property listings with more authentic and immersive real estate experiences for customers. Using Matterport, Jellis Craig Stonnington reduced its annual operating expenses by nearly AUD$200,000, achieved significant sales conversions, and leased 80 properties sight-unseen during a three-month period.

16:16 EDT Cohen & Steers reports preliminary AUM $94.2B as of May 31 - An increase of $1.4B from assets under management at April 30. The increase was due to net inflows of $760M and market appreciation of $815M, partially offset by distributions of $201M.

16:14 EDT Lordstown extends decline, down 9% to $10.19 after RBC puts $5 target on shares

16:13 EDT UiPath sees FY22 ARR $850M-$855M

16:09 EDT Kiniksa announces U.S. patent for treatment of recurrent pericarditis - Kiniksa Pharmaceuticals announced that the U.S Patent and Trademark Office issued a patent covering methods of using ARCALYST in the treatment of recurrent pericarditis. The patent issued as U.S. Patent No. 11,026,997 and will expire on March 11, 2039. Kiniksa has exclusive rights to this patent under the ARCALYST License Agreement. "We believe this patent continues to strengthen our proprietary position on the FDA-approved use of ARCALYST in recurrent pericarditis and provides protection that extends approximately 11 years beyond orphan drug exclusivity and into 2039," said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa. "We continue to execute on our commercial strategy and look forward to providing our first full quarter ARCALYST sales in our second quarter earnings report."

16:06 EDT Inogen names Stanislav Glezer as Chief Medical Officer - Inogen announced that its board has appointed Dr. Stanislav Glezer as Inogen's Executive Vice President and Chief Medical Officer, effective June 21, 2021. Most recently, Dr. Glezer was with Becton, Dickinson and Company, a global medical technology company where he served as the Worldwide Vice President of Medical Affairs for Diabetes Care since September 2018 with Business Development responsibilities added under him since January 2021.

16:06 EDT Pegasystems expands share repurchase program to $60M - Pegasystems announced that its Board of Directors has authorized an expansion of the Company's current share repurchase program. Under this expansion, the expiration date of the Company's current stock repurchase program will be extended from June 30, 2021 to June 30, 2022, and the amount of stock the Company is authorized to repurchase has been increased from approximately $21.7M, the amount remaining in the current program, to $60M.

16:05 EDT Mesa Air reports 28,264 block hours in May 2021, up 134% - Mesa Airlines reported 28,264 block hours in May 2021, a 134% increase from May 2020 as a result of increased flying due to industry recovery from the COVID-19 pandemic. The company also reported a controllable completion factor of 99.84 percent and 100 percent for its American and United operations, respectively. Reports total completion factor for May 97.22%

16:00 EDT Frito-Lay to invest $200M to expand Rosenberg, Texas plant - Frito-Lay, a division of PepsiCo, along with Fort Bend County announced a $200M investment at its Rosenberg, Texas, site. The investment will add two manufacturing lines for Funyuns and tortilla chips, as well as increase capacity in its warehouse to enhance capabilities and enable future growth. Anticipated to be complete by 2023, the project will provide 160 new, full-time jobs. The Frito-Lay Rosenberg facility today employs more than 750 full-time plant and fleet associates and produces more than 117 million pounds of snacks annually. "We've called Rosenberg home for nearly 40 years. Throughout that time, the support of Fort Bend County has helped us invest in the right areas so that we can continue to grow and provide jobs to the community," said Laura Maxwell, senior vice president of supply chain, PepsiCo Foods North America. "The Rosenberg site has the largest footprint of any Frito-Lay facility in Texas, producing snacks for Texas, Louisiana, Oklahoma, Kansas and Georgia, and several other parts of the country when we hit times of peak demand. We thank Fort Bend County for bringing investments like this to life."

15:46 EDT SkyWater Technology names Amanda Dnaiel CHRO - SkyWater Technology announced the appointment of Amanda Daniel as the company's first Chief Human Resources Officer. SkyWater's growth strategy depends on attracting and retaining top talent. "We are focused on optimizing our performance-driven culture as we aggressively expand and scale our Technology as a Service (TaaS) business model across the semiconductor industry," said Thomas Sonderman, SkyWater president and CEO. "Amanda has the right expertise to help SkyWater rapidly adopt and integrate best in class human resource practices. By implementing the right programs, systems, and processes, SkyWater will continue to create an environment that inspires the best talent to co-create the future with our customers." Daniel's previous experience includes most recently serving as senior vice president and CHRO at MTS Systems Corporation.

15:41 EDT Lordstown Motors trading resumes

15:13 EDT Lamont commends Connecticut Senate for approving adult-use cannabis legislation - Governor Ned Lamont is commending the Connecticut State Senate for voting to approve legislation drafted with the support and input of his administration that will legalize the recreational, adult-use of cannabis, including its sale and safe regulation. The legislation, Senate Bill 1118, next needs to be approved by the Connecticut House of Representatives before it can be transferred to Governor Lamont's desk and signed into law. Governor Lamont added: "This measure is comprehensive, protects our children and the most vulnerable in our communities, and will be viewed as a national model for regulating the adult-use cannabis marketplace. I look forward to the Connecticut House of Representatives securing passage of this measure and sending it to my desk." Publicly traded companies in the cannabis space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC), Tilray (TLRY), Trulieve Cannabis (TCNNF) and Zynerba (ZYNE). Reference Link

14:14 EDT MGM Resorts names Tilak Mandadi chief strategy, innovation, & technology officer - MGM Resorts International announced that Tilak Mandadi will join the company July 6th in the newly created position of Chief Strategy, Innovation & Technology Officer. In this role, Mandadi will oversee MGM Resorts' digital strategy, driving growth and innovation through technology-led customer-centric experiences, products and services. He will also lead corporate strategy and innovation, and will manage the company's relationship with BetMGM, joining its Board of Directors. He will be based in Las Vegas and report to MGM Resorts CEO & President Bill Hornbuckle.

12:49 EDT Capcom's 'Resident Evil Village' tops PlayStation Store's May downloads on PS5 - Sony (SONY) said that Capcom's (CCOEY) latest game "Resident Evil Village" topped May's PlayStation Store download charts for PlayStation 5 in both Europe and U.S./Canada, as well as the EU PlayStation 4 charts. Sony-published "Returnal," EA's (EA) "FIFA 21," and Sony-published "MLB The Show 21" were also high on the PS5 charts as well, while Microsoft-published (MSFT) "Minecraft" and EA's "Mass Effect Legendary Edition" earned high placements on PS4. Beat Games' "Beat Saber" and Activision's (ATVI) "Call of Duty: Warzone" continue to dominate on the PS VR and Free-to-Play charts, respectively, Sony said. Reference Link

12:34 EDT NeuBase announces data for mouse model of myotonic dystrophy type 1 - NeuBase Therapeutics announced new data and program updates for its development pipeline of PATrOL-enabled genetic medicines. Experiments conducted in the HSALR transgenic mouse model of myotonic dystrophy type 1, which express high levels of mutant CUG-repeat-containing mRNA in skeletal muscle, demonstrated molecular rescue in vivo after a single intravenous dose, which resulted in: ~75% splice correction of mis-spliced transcripts observed at ~2 weeks; Complete splice correction of chloride channel in skeletal muscle, a transcript responsible for the myotonia phenotype; Restoration of Clcn1 protein in skeletal muscle; Reduction of nuclear inclusions at day 21; and good tolerability at pharmacologically active doses, the company said in a statement. NeuBase CEO Dietrich Stephan said, "We successfully demonstrated that our platform can therapeutically modulate in vivo gene function at the DNA or RNA level with exquisite precision of target engagement in three different disease indications with different mechanisms of disease. These data show how we can utilize the PATrOL platform to design drug candidates to inhibit DNA transcription, RNA translation, and mutant protein production, as well as displace bound proteins to rescue mis-splicing...With this tremendous momentum building across our expanding development pipeline, we look forward to entering the clinic with our DM1 program in 2022 and continuing to evaluate diseases where our PATrOL platform can deliver significant therapeutic value."

12:03 EDT Cinemark expanding its in-theatre and online esports offering - Cinemark Holdings announced it is further innovating its entertainment experience by expanding its in-theatre and online esports offering. This summer, Cinemark customers will have the ability to join drop-in games in select theatres, and a new partnership with Mission Control will offer online esports leagues. For all details how to participate, visit Cinemark.com/gamebig. At Cinemark, we strive to continually evolve as an entertainment destination, offering our customers the opportunity to have an entertaining escape into more than just big films," said Justin McDaniel, Cinemark SVP of Global Content Strategy. "Our immersive environment lends itself particularly well to the gaming community, putting players in the universes in which they are competing. We are excited to bring big games to the big screen with our drop-in play as well as collaborate with Mission Control to offer online Cinemark esports leagues."

12:00 EDT Concord Medical falls -8.5% - Concord Medical is down -8.5%, or -29c to $3.17.

12:00 EDT Eastman Kodak rises 11.4% - Eastman Kodak is up 11.4%, or 99c to $9.66.

12:00 EDT Zhangmen Education rises 27.2% - Zhangmen Education is up 27.2%, or $4.39 to $20.52.

11:33 EDT Robinhood says identified options issue impacting some customers - Robinhood stated in a status message: "We've identified an issue that's causing some customers to encounter an error when trying to close an options position and are working to resolve it as soon as possible." Reference Link

11:04 EDT Boeing reports 73 gross commercial airplane orders in May - In data shared on its website, Boeing reported 73 gross orders in May for its commercial airplane programs. Boeing reported 17 deliveries in May for its commercial airplane programs. Reference Link

10:52 EDT Lydall up 5% after blog report claims company exploring possible sale - Shares of Lydall are up $1.81, or 5%, to $37.38 after Street Insider claimed in a blog post that a source said the company is exploring a potential sale. The company has hired an investment bank and at least two bids have been received, according to Street Insider's account of its source's report.

10:24 EDT Agco 'running a bit behind' in terms of sales in Q2 - Agco is having a "number of issues with component availability" and says these disruptions in getting parts are timing issues and won't impact demand, the company said at the Stifel Cross Sector Insight Conference. Still thinks FY21 results are going to be achieved.

10:12 EDT GE Healthcare sees FY21 revenue up low to mid single digits - Sees FY22 revenue "growing."

10:11 EDT Huntsman plans to increase production of EV battery materials - Huntsman announced that its Performance Products division is planning to significantly increase its existing capacity for ULTRAPURE Ethylene Carbonate at its Conroe, Texas facility by mid-2023. ULTRAPURE Ethylene Carbonate is critical to the reliable operation and long working life of lithium-ion batteries for electric vehicles and electronics. In recent years, Huntsman has seen strong growth in ULTRAPURE Ethylene Carbonate tied to the evolution of EVs and the localization of lithium-ion battery production. To meet this increased demand, Huntsman has added a range of new high-purity grades of Ethylene Carbonate for EV battery applications. "This capacity expansion will leverage our position as the only US producer of cyclic carbonates and support the rapid growth of the US and European lithium-ion battery markets for EVs," said Chuck Hirsch, Senior Vice President of Huntsman's Performance Products division. "We are committed to providing excellent service to our customers and are well positioned to grow with this sustainable industry, helping to reduce emissions in the transportation sector," he added.

10:00 EDT Oscar Health falls -6.7% - Oscar Health is down -6.7%, or -$1.96 to $27.29.

10:00 EDT Desktop Metal falls -9.3% - Desktop Metal is down -9.3%, or -$1.41 to $13.70.

10:00 EDT Duckhorn Portfolio rises 10.1% - Duckhorn Portfolio is up 10.1%, or $1.92 to $20.85.

09:55 EDT Simplicity Esports announces e-commerce platform for esports, gaming merchandise - Simplicity Esports and Gaming Company announced that it will go live with an e-commerce site in the month of July to sell esports and gaming related merchandise. The site will launch with an inventory of trading card games (such as Magic: The Gathering, Pokemom, and Yu-Gi-Oh!, and expand into gaming accessories and equipment. Simplicity Esports recently announced revenue for the months of March and April, and plans to file its audited fiscal year end report, 10-K in the next 90 days. Additionally, Simplicity Esports intends to list its common stock and warrants on The NASDAQ Capital Market or the NYSE American. There is no guarantee that the listing application will be approved by The Nasdaq Capital Market or the NYSE American.

09:47 EDT JanOne advances toward initiation of Phase 2b trial for JAN101 - JanOne announced the successful completion of Current Good Manufacturing Practices production of the first batch of JAN101 for its upcoming Phase 2b trial for treating Peripheral Artery Disease. The initial batch, produced by manufacturing partner CoreRX, contains approximately 200,000 sustained release tablets and matching placebos of JAN101, a patented sustained-release form of sodium nitrite aimed at improving vascular function and reducing neuropathic pain and other conditions resulting from poor blood flow. "Completion of the CGMP batch is an exciting achievement as we advance toward our planned Phase 2b PAD trial for JAN101," said Tony Isaac, President and Chief Executive Officer of JanOne. "With CGMP compliance, we've proven our ability to economically scale-up production of JAN101 while preserving the product's identity, strength, quality, and purity. We are now focused on bottling and labeling JAN101 for distribution to clinical test sites and engaging a contract research organization to manage our Phase 2b trial, including the recruitment of subjects." The FDA regulates the quality of pharmaceuticals through its main standard CGMP. Completion of CGMP production signifies that JanOne is fully compliant with the FDA's formal regulations regarding the design, monitoring, control, and maintenance of manufacturing processes and facilities for JAN101.

09:47 EDT Desktop Metal falls -6.9% - Desktop Metal is down -6.9%, or -$1.04 to $14.06.

09:47 EDT REV Group rises 9.7% - REV Group is up 9.7%, or $1.91 to $21.52.

09:47 EDT J.Jill rises 10.8% - J.Jill is up 10.8%, or $1.94 to $19.93.

09:39 EDT Arcimoto to join Russell 2000, Russell 3000 indexes - Arcimoto announced that it is set to join the Russell 2000 and Russell 3000 indexes at the conclusion of the Russell U.S. Indexes annual reconstitution, effective at the opening of the U.S. equity markets on Monday, June 28.

09:35 EDT HOOKIPA Pharma trading halted, volatility trading pause

09:33 EDT Dirtt Environmental opens manufacturing plant in South Carolina - DIRTT Environmental Solutions announces the opening of their newest manufacturing plant located in Rock Hill, within York County, South Carolina. The company's other manufacturing facilities are located in Phoenix, Arizona, Savannah, Georgia, and Calgary, Alberta, serving clients across the United States and Canada. An approximate $18.5M investment, the Rock Hill plant operates in a leased, custom-built 130,000 square foot building and is expandable to 260,000 square feet to support future growth. The plant is designed to maximize manufacturing of wall tiles, a key component of DIRTT's construction system. The new location also reduces shipping costs and transport times for customers located on the Eastern seaboard. DIRTT chose the Rock Hill location because it offers improved service to the Southeastern United States by balancing production facilities in Western Canada. Its proximity to Charlotte also allows for customers to visit the location as part of their experience. The plant will initially employ 25 permanent, full-time employees.

09:25 EDT Surna introduces EcoChill heat recovery chiller - Surna, operating as Surna Cultivation Technologies, introduces the addition of heat recovery chillers to its EcoChill product portfolio. "Two multi-state operators, in an effort to drive down operational costs, recently installed the EcoChill heat recovery chillers. The first MSO is a 90,000 square foot facility in Illinois and the other is a 40,000 square foot facility in Ohio. Because they produce both chilled and hot water simultaneously, EcoChill Heat Recovery Chillers can reduce the capacity requirements and energy consumption versus traditional 4-pipe chilled water systems," the company stated.

09:24 EDT Genius Brands set to join Russell 3000 Index - Genius Brands International announces it is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective when the US market opens on June 28, 2021, according to a preliminary list of additions posted on June 4, 2021.

09:21 EDT Flywire expands education business in Canada - Flywire announced the expansion of its digital education payments business in Canada. In response to client demand, Flywire is expanding the comprehensive receivables solution it offers to Canadian institutions, enabling them to support a variety of payment options on campus, including international, domestic, payment plans and more. "Flywire has already offered Canadian institutions the ability to digitize and streamline cross-border education payments for international students," said Sharon Butler, EVP of Education, Flywire. "Now, with the addition of our domestic payment offering in Canada, Flywire enables schools to seamlessly receive and reconcile payments from all students, all from within a single solution."

09:20 EDT Fortinet announces FortiMonitor, FortiAIOps offerings - Fortinet announced two new offerings to accelerate AIOps Network Operations with FortiMonitor and FortiAIOps. Fortinet is now extending network monitoring beyond the Fortinet Security Fabric to third party network infrastructures, applications and clouds, providing comprehensive Digital Experience Monitoring with FortiMonitor. FortiAIOps leverages artificial intelligence and machine learning models to eliminate manual analysis and correlates data from every network edge, automating anomaly detection.

09:18 EDT Reed's Virgil's launches three new zero sugar flavors - Virgil's announces the launch of three new Zero Sugar, Ketogenic Certified varieties: Grapefruit, Dr. Better and Ginger Ale. Crafted with natural ingredients, these new flavors can be experienced straight from the can, over ice, or mixed with a low-calorie cocktail.

09:18 EDT DOJ directs DEA, FBI, other departments to come up with body-worn camera plans - In a memorandum dated June 7, U.S. Deputy Attorney General Lisa Monaco said the Department of Justice is "committed to the use of body-worn cameras, or BWCs, by the Department' s law enforcement agents" in circumstances where the Department's agents encounter the public during pre-planned law enforcement operations. In this context, Monaco is directing the Acting Director of the Bureau of Alcohol, Tobacco, Firearms & Explosives; the Acting Administrator of the Drug Enforcement Administration; the Director of the Federal Bureau o flnvestigation, and the Director of the United States Marshals Service to develop and submit for review, within 30 days, component BWC policies that require agents to wear and activate BWC recording equipment for purposes of recording their actions during: a pre-planned attempt to serve an arrest warrant or other pre-planned arrest, including the apprehension of fugitives sought on state and local warrants; or the execution of a search or seizure warrant or order. Makers of body-worn cameras for law enforcement use include Axon (AXON) and Digital Ally (DGLY). Reference Link

09:16 EDT Telus Health mobile clinics help vaccinate Ontario residents - TELUS announced that through its innovative Health for Good program - in partnership with Waterloo's Sanguen Health Centre, Toronto's Parkdale Queen West Community Health Centre, and Ottawa's Inner City Health - COVID-19 vaccinations are being provided to at-risk and vulnerable residents of Ontario from its mobile health clinics, powered by TELUS Health. These specially-equipped clinics on wheels have been providing essential primary health and harm reduction services directly to individuals in the communities they serve since they launched in 2020. Operations have recently expanded to offer COVID-19 testing and vaccinations, following the provincial public health guidelines. Through relationships with local community centres, homeless shelters, and congregate housing facilities, the clinics have administered more than 1,500 doses of the vaccine to at-risk Ontarians, conducted 15,400 COVID-19 tests/assessments, and have supported nearly 30,000 patient interventions to-date.

09:13 EDT Glass Lewis recommends Leaf Group shareholders approve acquisition - Leaf Group (LEAF) announced that Glass, Lewis & Co. has recommended shareholders vote to approve its merger agreement with Graham Holdings Company (GHC). Deborah Benton, Leaf Group's Chair of the Board, commented: "With Glass Lewis, Institutional Shareholder Services Inc. and the Board all recommending that shareholders approve Graham Holdings' acquisition of Leaf Group, it is clear that voting for this transaction is the best path forward for all of our shareholders. As with ISS's report, the findings in Glass Lewis's report clearly demonstrate that the significant and immediate value created by this transaction far outweighs the potential value that might be generated by continuing to operate as a separate, standalone entity. The Board continues to unanimously recommend that the company's shareholders vote to approve the merger agreement." In addition, Glass Lewis joined ISS in recommending in its report that shareholders approve both of Leaf Group's related proposals, including the non-binding advisory proposal to approve the compensation of the company's executive officers in connection with the merger with Graham Holdings and the adjournment of Leaf Group's special meeting of shareholders in the event there are insufficient votes to approve the merger at the time of the special meeting.

09:09 EDT AMD announces AMD Radeon Pro W6000 series - AMD announced the AMD Radeon PRO W6000 series workstation graphics, delivering exceptional performance, stability and reliability for professional users. The new graphics products were designed and optimized to power demanding architectural design workloads, ultra-high resolution media projects, complex design and engineering simulations, and advanced image and video editing applications. Built on AMD RDNA 2 architecture, the foundation of next generation, high-powered PCs, laptops and many of today's game consoles, the new product line features the AMD Radeon PRO W6800, the fastest AMD RDNA workstation graphics card ever1. It also includes the AMD Radeon PRO W6600 graphics card, meticulously engineered for ultra-high performance workflows, and the AMD Radeon PRO W6600M GPU, designed to power professional mobile workstations.

09:07 EDT Varonis announces location in Cork, plans to double headcount to 120 employees - Varonis Systems announced the opening of its new and expanded office space in Cork City at Penrose Dock. Varonis is expected to double its employee headcount, creating approximately 60 jobs - ranging from tech support, research and development, human resources, and sales - over the next three years. Varonis is headquartered in New York City and today employs approximately 1,800 employees worldwide. The company opened its first Cork location in 2017.

09:06 EDT Synopsys acquires Code Dx - Synopsys announced that it has acquired Code Dx, a provider of an award-winning application security risk management solution that automates and accelerates the discovery, prioritization, and remediation of software vulnerabilities. The addition of Code Dx enables Synopsys to offer customers consolidated risk reporting and prioritization across correlated software vulnerability data produced by Synopsys solutions and more than 75 third-party and open source application security and development products. Headquartered in Northport, New York, the acquisition also adds a team of R&D engineers experienced in vulnerability correlation and integrating security testing activity across the entire software development pipeline. The terms of the deal, which are not material to Synopsys' financials, are not being disclosed.

09:04 EDT Citius schedules interim analysis in Phase 3 trial of Mino-Lok for end of June - Citius Pharmaceuticals announced that the next planned interim analysis in its Phase 3 trial of Mino-Lok, an antibiotic lock solution for the treatment of patients with catheter-related blood stream infections, or CRBSIs/CLABSIs, has been scheduled for the end of June. In accordance with the independent Data Monitoring Committee, or DMC, charter, the DMC will hold a meeting to review the trial data for safety, superiority and futility. According to the Mino-Lok Phase 3 study protocol, the DMC is responsible for conducting interim analyses when 40%, 50% and 65% of the total number of anticipated events have been observed.

09:03 EDT Liquid Media announce LOI to acquire Filmdab for up to 1.25M shares - Liquid Media announced the signing of a letter of intent to acquire Filmdab, which operates as "Filmocracy," a B2B2C film and festival streaming platform. Under the terms of the LOI, Liquid would acquire Filmocracy for up to 1.25M shares, and Filmocracy must achieve revenues totaling up to $66M to trigger three of the four equal tranches. "We are excited to be incorporating Filmocracy as an integral component of the Liquid Media solution for IP creators," says Ron Thomson, CEO of Liquid. "Filmocracy's team has established a powerful value proposition for extending the film festival experience across virtual audiences globally. In doing so, they are combining business-to-business and business-to-consumer models to increase revenues via SaaS sales, subscriptions, advertising, sponsorships and more. This is an explosive growth business assisting both content creators and festival operators to more effectively monetize their opportunities in new ways." Under the terms of the LOI, Liquid would acquire Filmocracy for up to 1.25M common shares of Liquid, which would be paid out to Filmocracy investors across specific performance milestones in four equal tranches of 312,500 common shares each. The first tranche of Consideration Shares would be payable upon closing, with three remaining milestones triggered by Filmocracy revenues totaling $66M in the years ahead. Additional cash would be invested in Filmocracy's ongoing operations, beginning with immediate availability of a secured bridge loan in the amount of $609K, to be applied towards working capital, technology infrastructure and marketing. Final terms of the acquisition will be negotiated and memorialized in binding and definitive documentation to be entered into at or prior to closing. Completion of the acquisition is subject to, among other things, customary due diligence as well as any necessary share issuance requirements and approvals.

09:03 EDT Hyster expands electric lift truck portfolio with cushion tire model - Hyster Company announces the release of its new E50-60XNL series, the industry's first cushion tire counterbalanced lift truck available in the 5,000-to-6,000-pound capacity range specifically designed around factory integrated lithium-ion power. Expanding on the GOOD DESIGN pneumatic tire model in the same capacity range released last year, the E-XNL also addresses the growing demand for electric lift truck solutions for a broad range of intense applications, including general manufacturing, metals, paper and packaging.

09:01 EDT Westport announces closing of marketed public offering - Westport Fuel Systems announced the closing of its previously-announced underwritten marketed public offering of common shares in the United States and Canada for gross proceeds to the Company of $115,115,000. The Company issued a total of 20,930,000 shares, including 2,730,000 shares following the exercise in full by the underwriters of their over-allotment option. The shares were issued at a price to the public of US $5.50 per share. Westport Fuel Systems intends to use the net proceeds of the Offering primarily for capital expenditures to expand and automate production capacity of the Company's high pressure direct injection products to meet customer demand, and to advance the research and development of the Company's HPDI technology to decarbonize transportation economically and efficiently, including using hydrogen fuel. The remainder of the funds are to be allocated for potential acquisitions of bolt-on businesses that offer complementary capabilities or technologies to existing businesses, to further strengthen the balance sheet, as well as for general corporate purposes.

08:57 EDT Reliance Global schedules commercial launch of 5minuteinsure.com - Reliance Global Group announced plans for the commercial launch of its 5minuteinsure.com platform in Q3 2021 and reports that its new demo video is available on the Company's website. 5minuteinsure.com is designed to utilize artificial intelligence to provide competitive insurance quotes online within five minutes, with minimal data input by the customer. 5minuteinsure.com combines the best of a traditional insurance agency, including the option for direct agent interaction with the ability to bind a policy either online or offline.

08:55 EDT Paya platform achieves certification for Acumatica's 2021 R1 update - Paya announced that its platform has achieved certification for Acumatica's 2021 R1 update, available across all of Acumatica's ERP editions and customer portal. Paya's advanced solution enhances back-office efficiency, offers features such as e-invoicing, automated card account updater and recurring billing. Paya delivers seamless card, ACH, and check payment acceptance, reporting, and reconciliation functionality directly into management workflows.

08:51 EDT GBS Inc. announces results from global glucose monitoring survey - GBS announced survey results from more than 300 patients globally as part of its development and go-to-market strategy. As GBS is advancing to clinical trials of its saliva glucose biosensor, it conducted a global voice of customer survey of diabetes patients to verify the desirability, discuss the applications in daily life and review the product features of its Saliva Glucose Biosensor. The comprehensive global survey featuring more than 300 patients worldwide living with diabetes revealed strong support for a non-invasive alternative to current Standards of Care (SOC) in glucose monitoring. In all target markets, 90% of patients responded positively to the Biosensor Platform. 7 out of 10 patients were "seriously interested" in purchasing the product when it's released, and 3 out of 10 wanted to be placed on the waiting list ahead of release. While patients in the U.S. indicated the price of a pain-free alternative to current glucose monitoring would play a role in determining their decision to upgrade to a new device, patients in China indicated price was not an issue, as long as the product was accurate and reliable. All devices currently available to monitor glucose levels require patients to pierce their skin and fall into three main categories: Self-monitoring blood glucose devices, where people prick their finger up to 10 times per day for testing. Continuous glucose monitoring devices, where glucose levels in fluid surrounding body cells are automatically tested with a sensor inserted under the skin and is accompanied by finger-pricking to test blood glucose when required. Flash glucose monitoring devices, where glucose levels in interstitial fluid are monitored with a sensor inserted on a patient's upper arm and a separate touchscreen reader device provides analysis, however, finger-pricking is required to test blood glucose when needed. The Saliva Glucose Biosensor is the first innovation to be developed from the Biosensor Platform and is currently being developed by GBS as a point-of-care test intended to provide patients a favorable solution to finger-prick blood glucose testing when monitoring diabetes. This alternative test offers a pain-free option to current testing methods by using an organic thin film transistor, incorporating Glucose Oxidase as the recognition element to initiate an electrochemical reaction that produces an electrical signal to display glucose measurements in real-time on an app or dedicated device. GBS intends to leverage this global survey data as part of its development and commercialization strategy once approved by healthcare regulatory agencies in the United States, Europe and Asia.

08:47 EDT Microchip announces qualifatication of MOSFET for space applications - Microchip Technology announced the qualification of its M6 MRH25N12U3 radiation-hardened 250V, 0.21 Ohm Rds, metal-oxide-semiconductor field-effect transistor for commercial aerospace and defense space applications. Microchip's radiation-hardened M6 MRH25N12U3 MOSFET provides the primary switching element in power conversion circuits including point-of-load converters, DC-DC converters, motor drives and controls and general-purpose switching. The MOSFET withstands the harsh environments of space, extends reliability of power circuitry and meets all requirements of MIL-PRF19500/746 with enhanced performance. Microchip completed testing for Defense Logistics Agency (DLA) review and qualification, for the device's sourcing in the U.S. military supply chain (expected JANSR2N7593U3 certification in June 2021).

08:45 EDT Phunware release 'PhunWallet' mobile app - Phunware announced the initial release of its new mobile application software, PhunWallet, on Google Play for Android. PhunWallet is a cryptocurrency wallet and mobile application that supports Phunware's blockchain-enabled data exchange and mobile loyalty ecosystem powered by PhunCoin and PhunToken, respectively. While PhunCoin is a regulated store of value that seeks to compensate users for their data, PhunToken is intended to be a medium of exchange that promotes profitable behavior by unlocking key features of Phunware's Multiscreen-as-a-Service platform that reward and measure engagement. The Company expects to release PhunWallet for iOS users by the end of the month, subject to Apple App Store approval.

08:43 EDT Ocean Power announces planned transfer of Nasdaq listing to NYSE - Ocean Power Technologies announced that it will change its listing from the Nasdaq Capital Market to the NYSE American stock exchange. The last day of trading on the Nasdaq Capital Market is expected to be Thursday, June 17, 2021. OPT expects to commence trading as an NYSE American-listed company when markets open on Friday, June 18, 2021. The company's common stock will continue to trade under its existing "OPTT" symbol.

08:42 EDT Colony Capital announces corporate rebranding, to change name and symbol - Colony Capital announced a corporate rebranding of the company to DigitalBridge, effective June 22. Digital Colony, the company's digital infrastructure investment platform, will also change to operate under the DigitalBridge brand. In connection with the transition, the corporate name will be changed to DigitalBridge Group, and the company will begin trading under a new NYSE ticker symbol, (DBRG), as of June 22. The company said, "The new name reflects the significant business transformation the Company has undergone since the leadership and board of directors made the bold decision to chart a new direction - years ago - realigning a diversified real estate investment firm to focus exclusively on the fast-growing digital infrastructure sector. The 'new' name, DigitalBridge, re-establishes and renews the original Digital Bridge, which combined with the Company in 2019, evoking its heritage as an early innovator in digital infrastructure, while looking forward to a fully digital, interconnected future." The company intends to share more information about its strategy and rebranding, including a new logo at its inaugural Investor Day, to be held on June 22.

08:41 EDT Revive Therapeutics partners with Supriya to pursue EUA for bucillamine - Revive Therapeutics announced it has entered into a memorandum of understanding dated June 7, 2021 with Supriya Lifescience, a specialty pharmaceutical company based in India, to pursue manufacturing of the API, conducting clinical registration and commercialization for Bucillamine to treat COVID-19 through Emergency Use Authorization in India. The relationship also sets the foundation for Revive to expand commercialization efforts globally by leveraging Supriya's extensive manufacturing and commercial network and Revive's ongoing US FDA Phase 3 clinical study results of Bucillamine to treat mild-to-moderate COVID-19.

08:39 EDT Rapid development of Cannabinoid based medicinal products 'reaching new levels' - The recent pandemic has, as we all know, negatively affected almost every business and financial markets across the globe... and even the seemingly ever increasing Cannabidiol markets. The global COVID-19 pandemic outbreak has had an unprecedented and staggering impact on the global economy. This has negatively affected the demand for cannabidiol across all regions amid the pandemic. The global market exhibited a lower growth of 26.42% in 2020 compared to the average year-on-year growth during 2017-2019, however the market is projected to get back on the fast track grow from USD 3,675.1 million in 2021 at a CAGR of 47.49% between 2021 and 2028. The substantial rise in CAGR is attributed to the market's demand and growth, coupled with the market functioning returning to pre-pandemic levels once the pandemic is over. Industry reports, see higher acceptance from consumers, increasing government approvals and R&D on uses of medicinal cannabis will spur the markets higher for years to come. A report from Fortune Business Insights said that: "Consumers seek innovative and healthy food products enriched with nutrients for achieving fitness goals and avoid injuries such as inflammation, pain, and others. The manufacturers are introducing products infused with novel ingredients such as CBD oil. Cannabidiol oils are the legalized and non-psychoactive element of cannabis that has conquered several industries such as food, health products, pharma & beauty, and others. According to the Harvard Health Institute 2018, CBD is commonly utilized to address human life's health issues such as insomnia, anxiety, etc. Thus, the demand for such innovative CBD products from the consumer end proliferates to maintain a healthy life balance." Active Companies active today in the cannabis related markets include: Jazz Pharmaceuticals (JAZZ), Rapid Therapeutic Science Laboratories, Inc. ( RTSL), Intec Pharma Ltd. (NTEC), Cara Therapeutics, Inc. (CARA), Arena Pharmaceuticals ARNA).

08:37 EDT Brink's affirms 2021 revenue growth guidance of 21%, $4.45B at the midpoint - Two est. $4.41B. The Brink's Company announced that it affirmed its 2021 guidance including revenue growth of 21% to approximately $4.45B at the midpoint, which is up 10% on an organic basis. The company expects 2021 adjusted EBITDA growth of 25% to approximately $705M. In 2022, management is targeting organic revenue growth of 5% to 7%, adjusted EBITDA growth in the mid-teens to a range between $785M and $825M, and free cash flow growth of more than 50% to a range between $350M and $400M. The company provided the update in advance of its June 8 participation in the 2021 Baird Global Consumer, Technology and Services Conference. Doug Pertz, president and chief executive officer, said: "Based on improving economic trends in most of our major markets, and the continued strong use of cash as a major method of payment, we continue to expect an accelerating recovery from the global pandemic. On an organic basis, excluding the impact of acquisitions and foreign exchange, year-to-date revenue through April has recovered to 96% of pre-pandemic 2019 pro forma levels. We are particularly encouraged by the fact that our revenue recovery through April was achieved despite unforeseen pandemic-related shutdowns in several European and South American countries. We expect revenue and profit growth to accelerate as we move through 2021, especially in the second half. Our confidence is based on a continued global economic recovery, growing contributions from the G4S and PAI acquisitions, the impact of our cost reductions, and normal seasonality. Our 2021 guidance, and our expected post-pandemic return to mid-single-digit organic revenue growth and double-digit profit growth, are driven primarily by our core operations. Our strategy 2.0 digital initiatives, with the exception of the PAI acquisition, are not included in our current outlook for 2021 or 2022, though we expect these initiatives to drive additional organic revenue and profit growth in 2022 and beyond. We plan to disclose additional financial targets for 2022 and 2023 at our Investor Day event in November."

08:34 EDT MiMedx receives regulatory approval to commercialize EPIFIX in Japan - MIMEDX announced successful regulatory approval by the Japanese Ministry of Health, Labour and Welfare to market EPIFIX in Japan. MIMEDX submitted a Shonin to the JMHLW, Japan's primary regulatory body for creating and implementing safety standards for drugs and medical devices, and the Pharmaceutical and Medical Device Agency, an independent administrative agency that works with JMHLW to ensure the safety and quality of drugs and medical devices, in mid-2020. EPIFIX was approved for hard-to-heal chronic wounds, such as diabetic foot ulcers and venous leg ulcers, which do not respond to conventional therapy. EPIFIX will be classified as a Class IV Medical Device and "Specified Biological Product" under JMHLW guidelines. The company is currently working with JMHLW to establish reimbursement pricing, a process expected to take up to six months. Once a reimbursement pricing policy is approved and the reimbursement rate is listed, the company can begin offering EPIFIX to patients and providers in Japan.

08:33 EDT Plains All American executes agreements for sale of natural gas storage assets - Plains All American and Hartree Partners announced the execution of definitive agreements whereby Plains will sell its Pine Prairie and Southern Pines natural gas storage facilities to an affiliate of Hartree for a total cash consideration of $850M. The assets included in the transaction consist of approximately 70 billion cubic feet of total working gas capacity across nine caverns, along with associated base gas, header pipelines and compression facilities. Subject to the receipt of regulatory approvals and customary closing conditions, the transaction is expected to close in the third quarter of 2021. As of June 30, 2021, Plains will re-classify the assets associated with the transaction to "held for sale" on its balance sheet and recognize a corresponding non-cash loss of approximately $480M in accordance with GAAP requirements.

08:32 EDT CLPS forms joint venture with Columbus Century Development - CLPS announced that it has formed a joint venture with Columbus Century Development, a blockchain technology solutions provider. The joint venture aims to develop and upgrade blockchain-based digital asset solutions for financial institutions. Such digital asset solutions include custody, exchange, payment, and non-fungible token, or NFT, distribution platforms, particularly in wealth management and various investment transactions, among others. On June 4 CLPS, through its wholly owned subsidiary, Growth Ring, entered into a shareholder agreement with Columbus. Pursuant to the Agreement, both parties have agreed to establish a British Virgin Islands joint venture company within 30 days after the signing, and will eventually plan to set up wholly owned subsidiaries in Hong Kong SAR and Hainan. Upon closing of the transaction, CLPS and Columbus will hold 55% and 45% of the Joint Venture's shares, respectively.

08:27 EDT ArcelorMittal announces results of General Meetings - The Annual General Meeting and Extraordinary General Meeting of shareholders of ArcelorMittal held approved all resolutions by a strong majority. Over 73.5% of the voting rights were represented at the General Meetings. In view of the Covid-19 outbreak, the Board of Directors of ArcelorMittal had decided to hold this year's General Meetings by virtual-only format, as permitted by Luxembourg law. The meeting was preceded by a virtual one-hour Q&A session with shareholders. Arrangements were made to allow shareholders to vote electronically and by proxy voting. The results of the votes will be posted shortly on https://corporate.arcelormittal.com under 'Investors - Equity investors - Shareholders events - AGM - General Meetings of shareholders, 8 June 2021' where the full documentation regarding the General Meetings is available. In particular, the shareholders, approved the distribution of a dividend of 30c per share, the re-election of Mrs. Karyn Ovelmen and Mr. Tye Burt and the election of Mrs. Clarissa Lins as directors of ArcelorMittal, for a term of three years each. Shareholders also approved the decision to cancel shares and to consequently reduce the issued share capital following the cancellation of shares repurchased under its share buyback program as required.

08:25 EDT AYRO receives $2M purchase order for new Club Car current EV - AYRO announced the receipt of an initial purchase order valued at $2M, subject to the terms and conditions of the Master Procurement Agreement executed March 13, 2019. This immediately follows the launch of the 2022 Club Car Current, the next generation of the Club Car 411. "This first purchase order signals the strong, and immediate, demand for the Club Car Current as business sustainability goals and EV adoption increase," the company said. "Club Car has been a strong partner for getting our light-duty, low-speed EVs to customers that need them, and this purchase order is a great example of our successful collaboration," said Rod Keller, CEO of AYRO. "The Club Car Current navigates campuses and narrow urban streets seamlessly while also carrying significant loads for meeting last-mile distribution challenges-this is something most other EV's are not designed to handle." Karma Automotive will assemble the Club Car Current at its Innovation and Customization Center in Moreno Valley, California as part of its strategic partnership with AYRO announced last year.

08:21 EDT Immutep announces anti-LAG-3 research program - Immutep is pleased to provide an update on its preclinical development pipeline. Under the collaboration project commenced in 2019 with Cardiff University, the Company has advanced the discovery and development of a new generation of small molecule anti-LAG-3 therapies. The ultimate aim of the project is to make an oral treatment available to cancer patients and at a lower cost compared with the current anti-LAG-3 antibodies being developed by several companies. The project brings together Immutep's deep experience in LAG-3 biology, with the expertise of Cardiff University Professors Andrew Godkin and Andrea Brancale. Prof Godkin is the University Theme Lead in Immunology in the College of Biomedical Life Sciences and Prof Brancale is Professor of Medicinal Chemistry at the School of Pharmacy and Pharmaceutical Sciences. Under the Agreement, all intellectual property relating to lead compounds as well as derivatives thereof, will be jointly owned by Immutep and Cardiff University. Immutep will have exclusive rights to develop and commercialise the new molecules in the clinic according to pre-defined licensing terms. The Agreement builds on a Material Transfer Agreement signed by Immutep SAS and Cardiff University in 2015. As announced on 31 August 2020, the Australian Research Council awarded Immutep and research partner Monash University a grant under the ARC's Linkage Project scheme to support their research collaboration into LAG-3 for a further three years. Monash University's research team for the project is led by Professor Jamie Rossjohn, an ARC Laureate Fellow at the Monash Biomedicine Discovery Institute and Professor in Structural Immunology at Cardiff University.

08:18 EDT Homeowners of America introduces services in Illinois - Homeowners of America announced the launch of service in Illinois. Porch completed its acquisition of HOA in April 2021 with plans to drive growth in HOA's current markets and begin national expansion. HOA now operates in seven states including Illinois. Porch is supporting HOA insurance operations expertise with its low cost and early access to homebuyers who need insurance and robust property data that is unique to Porch.

08:18 EDT Exela Technologies extends partnership with care services insurance company - Exela Technologies announced extension and expansion of its partnership with one of the largest specialty care services insurance carriers in the country. This engagement leverages Exela's powerful cloud-based digital exchange platform for the insurance industry, PCH Global, that provides a single point of access for claims management, correspondence and payments, to expand the current deployment to approximately 3,800 specialists as registered users within the customer organization using Exela's proprietary workflow and rule engines across all aspects of the health claims spectrum including behavioral health. As part of a broader evolution of this relationship, Exela will collaborate with the customer to ultimately connect 27,000 unique providers to PCH Global to help drive digital clean claims submission and communication to improve transparency and reduce administrative costs. Exela continues to invest in expanding PCH Global capabilities to provide a cloud hosted solution with one of the best edit resolutions for healthcare claims. This expansion of deployment marks another milestone in PCH Global platform's growing value proposition in healthcare to digitally connect members, providers and insurance companies for clean claims, payment transparency and digital appeals.

08:17 EDT Myomo provides update on CMS discussions - Myomo provided an update regarding its application for a Healthcare Common Procedure Coding System Level II code change and benefit category redetermination for HCPCS codes L8701 and L8702 submitted in January 2021. The Centers for Medicare & MedicaidCMS-1738-P, "Medicare Program; Durable Medical Equipment, Prosthetics, Orthotics and Supplies policy Issues and Level II of the Healthcare Common Procedure Coding System (HCPC mitigation plan.(85 Fed. Reg. 70358, November 4, 2020). With the change in CMS leadership and continued COVIDning, finalization of the Proposed Rule has been delayed. As a result, Myomo withdrew its HCPCS code change application and intends to meet with CMS to continue discussions for finalizing the appropriate Medicare benefit category, coverage and fee publications for HCPCS codes L8701 and L8702. The Company intends to continue with its current business strategy of serving patients with certain Medicare Advantage, commercial and government health insurance plans. Paul R. Gudonis, Chief Executive Officer of Myomo commented, "Since a new CMS Administrator was only recently confirmed, we decided that it was in the Company's best interest to withdraw our application until the Proposed Rule is finalized. We intend to resubmit our coding application at that time. Due to recent actions by the new Administration, over 800,000 more Americans now have access to health insurance and we are pleased to see this broader access. We look forward to working with new CMS leadership and staff to enable more individuals with dysfunctional arms to gain access to a MyoPro brace to restore their arm and hand function and reduce their overall cost of care."

08:16 EDT iCAD signs global distribution agreement with Sectra - iCAD announced it has signed a worldwide distribution agreement with Sectra. Through this agreement, ProFound AI and ProFound AI Risk will be offered through the Sectra Amplifier Marketplace, which will expand their access to more facilities and imaging centers worldwide. "iCAD's technology offers unparalleled benefits to clinicians and patients alike. ProFound AI is clinically proven to enhance breast cancer screening by improving radiologists' accuracy and efficiency. ProFound AI Risk is the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation that is personalized for each woman, based solely on a screening mammogram," according to Michael Klein, Chairman and CEO of iCAD. "These technologies empower clinicians to provide more accurate and personalized breast cancer screening."

08:14 EDT Pioneer, Cerence enter strategic partnership to develop AI solutions for cars - Pioneer and Cerence announced that the companies have reached an agreement for a strategic partnership to develop scalable, secure, AI-powered products and services for the mobility world. The intent of the agreement is to combine the technologies of Pioneer, which provides in-car equipment and mobility services, and Cerence, which provides conversational AI to mobility OEMs and automakers, to utilize the companies' respective knowledge and technologies to "accelerate innovation and develop products and services that enhance mobility experiences for drivers and passengers globally," the companies said. "Together, the companies will jointly develop an integrated hardware and software product based upon Pioneer's industry-leading technological capabilities and solution services, globally deployed in more than 10M in-car infotainment systems annually, and Cerence's AI-powered automotive assistant platform that leverages cloud-based conversational AI to deliver an intuitive, intelligent in-car experience that makes travel safer, smarter and more comfortable," the companies added.

08:13 EDT IntelGenx enters Materials Transfer Agreement with veterinary health company - IntelGenx announced that it has entered into a Materials Transfer Agreement with an undisclosed global veterinary health company. Pursuant to the Agreement, the Partner will evaluate IntelGenx's proprietary VetaFilm platform in cats. Based on a successful evaluation, IntelGenx and the Partner will enter into negotiations for a commercial agreement in the veterinary field.

08:12 EDT PEACE Cable, PCCW Global use Infinera's ICE6 for PEACE submarine cable system - PEACE Cable International Network and PCCW Global announce that they will deploy the Infinera ICE6 optical engine solution on the Mediterranean Segment of the Pakistan & East Africa Connecting Europe, or PEACE, submarine cable system. The Infinera optical engine solution will provide the PEACE submarine cable system with the ability to transmit a capacity of nearly 25 terabits per fiber pair.

08:10 EDT Guardant Health appoints Chris Freeman as Chief Commercial Officer - Guardant Health announced the appointment of Chris Freeman as the company's new Chief Commercial Officer for its oncology business, effective June 8, 2021. Chris brings significant experience successfully building and managing pharmaceutical and biotechnology brands through all stages of commercialization, which will be invaluable as the company's oncology portfolio expands to cover advanced and earlier stage cancers.

08:09 EDT Aqua Metals to join Russell Microcap Index - Aqua Metals announced that it will join the Russell Microcap Index effective June 28, 2021, at the conclusion of the 2021 Russell Microcap Index's annual reconstitution. Aqua Metals was identified on the preliminary list of additions that were posted on June 4, 2021.

08:08 EDT Pacific Mercantile provides $7.5M line of credit to Mason-West - Pacific Mercantile Bank (PMBC), the wholly owned subsidiary of Pacific Mercantile Bancorp, announced that it has provided a $7.5M revolving line of credit to Mason-West, the western regional distributor of engineered seismic restraint systems and vibration isolation products manufactured by Mason Industries. Along with the financing, Mason West utilizes a full suite of Pacific Mercantile Bank's treasury management products and services. Mason West is a portfolio company of Gladstone Investment Corporation (GAIN) and KCM Capital Partners.

08:05 EDT Kratos Defense completes milestone for advanced space radio monitoring system - Kratos Defense & Security Solutions announced that it has successfully completed the Critical Design Review for the build out of the advanced space radio monitoring system for the Communications Regulatory Authority of the State of Qatar. The advanced space radio monitoring system includes a fixed site and mobile unit to monitor satellite downlinks to manage and protect the spectrum. The comprehensive system includes Kratos' antennas, satellite monitoring and geolocation products, and an Unmanned Aerial Vehicle spectrum analysis solution to detect and mitigate any potential interference events.

08:04 EDT Service Finance Company launches home improvement program with Sam's Club - Service Finance Company and Sam's Club announced the launch of a new home services program, Sam's Club Home Install Experts by Service Finance, that connects Sam's Club members with highly-rated local home improvement contractors that have been vetted by Service Finance and enrolled as authorized Service Finance Dealers. Products and Services available through this program include HVAC, roofing, siding, window and door installation, bathroom renovations, kitchen renovations, as well as gutters and flooring products. The relationship with Sam's Club comes as Americans continue to invest in home renovation and improvement projects. Sam's Club Home Install Experts by Service Finance takes the guesswork out of finding and securing a home improvement contractor with its simple online platform - giving Sam's Club members the additional benefit of 10% Discount Off Everyday Dealer Pricing with promotional financing available through Service Finance Dealers.

08:03 EDT Funds managed by affiliates of Apollo Global to acquire TOPS from Black Bay - Funds managed by affiliates of Apollo Global Management announced that they have acquired a majority interest in Total Operations and Production Services from Black Bay Energy Capital. TOPS is a leading provider of contract gas compression services for the Permian Basin, with a focus on electric driven compression systems that offer customers improved performance and reduced emissions. TOPS will continue to be headquartered in Midland, Texas and led by L.D. Green, Chief Executive Officer, and Brian Green, Chief Operating Officer. The investment from the Apollo Funds will help TOPS support continued growth in customer demand and allow TOPS to expand its capabilities to better serve the growing market for electric driven compression for gas lift and other applications. TOPS' proprietary electric compressor design and controls continue to gain traction in the market as operators seek to reduce costs, increase runtime and lower carbon footprints. Vinson & Elkins LLP acted as legal counsel to the Apollo Funds. Fishman Haygood acted as legal counsel to TOPS and Black Bay. J.P. Morgan supported the transaction through an upsized credit facility.

08:02 EDT Inovio to expand partnership with Advaccine Biopharmaceuticals Suzhou - INOVIO announced an expansion of its previously announced partnership with Advaccine Biopharmaceuticals Suzhou to jointly conduct a global Phase 3 segment of the ongoing Phase 2/3 trial called INNOVATE. Together, the companies will evaluate the safety and efficacy of INO-4800 in a two-dose regimen, administered one month apart, in a two-to-one randomization in subjects 18 years and older across several countries, primarily in Latin America and Asia. The primary endpoint of the Phase 3 segment will be virologically confirmed COVID-19 disease. The 2.0 mg dose was selected from the Phase 2 segment, where INO-4800 was shown to be generally well-tolerated and immunogenic in all tested age groups.

07:59 EDT Thryv Holdings set to join Russell 2000 Index - Thryv Holdings announced the Company is expected to be included in the Russell 2000 Index and the broad-market Russell 3000 Index effective after the U.S. market opens on June 28, 2021, as part of the annual reconstitution of the Russell stock indexes.

07:55 EDT Orezone Gold reports initial results from drilling program at Bombore - Orezone Gold Corporation announced initial results from its ongoing drilling program to test the expansion potential at the P17S deposit at its Bombore Gold Project, located in Burkina Faso. The drilling program has been very successful returning the best hole to date at P17S with several other wide, multigram gold intercepts near surface outside of the current reserves and resource envelopes. These drill results intersected multiple high-grade stacked zones of mineralization to the north of the P17S reserves including a new wide, shallowly dipping zone with excellent down-plunge continuity. This clearly demonstrates the potential to add significant high-grade resources commencing near surface at P17. Drilling Highlights: 32 m of 3.87 g/t gold from 25 m including 6 m of 14.40 g/t gold from 34 m in BBD1066; 30 m of 2.76 g/t gold from 15 m including 8 m at 5.50 g/t gold from 17 m in BBD1048; 22 m of 1.97 g/t gold from 24 m in BBD1052; 20 m of 1.54 g/t gold from 54 m in BBD1060; 7 m of 4.13 g/t gold from 35 m in BBD1062; 5 m of 4.89 g/t gold from 54 m in BBD1062; 6 m of 3.54 g/t gold from 39 m in BBD1055; 18 m of 1.70 g/t gold from 62 m in BBD1044; 14 m of 1.64 g/t gold from 7 m in BBD1045; 9.5 m of 1.56 g/t gold from 12.5 m in BBD1046; 15 m of 1.40 g/t gold from 39 m in BBD1053; 12 m of 1.85 g/t gold from 177 m in BBD1055; 7.10 m of 2.64 g/t gold from 113 m in BBD1060; 3.5 m of 3.65 g/t gold from 176 m in BBD1057; 11 m of 2.14 g/t gold from 75 m in BBD1048.

07:50 EDT Field Trip Health applies to list common shares on Nasdaq Stock Market - Field Trip Health announced that it has applied to list its common shares on the NASDAQ Stock Market. By the end of 2021, Field Trip anticipates being able to commence Phase 1 human trials for FT-104 and expects to have 20 Field Trip Health centers operating or under construction, including its existing and announced locations in New York, NY, Toronto, ON, Los Angeles, CA, Chicago, IL, Houston, TX, Atlanta, GA, San Diego, CA, San Jose, CA, Seattle, WA, Washington, DC, Fredericton, NB and Amsterdam, NL. In advance of an anticipated listing on NASDAQ, Field Trip will file a Registration Statement with the United States Securities and Exchange Commission. The listing of Common Shares on NASDAQ remains subject to the review and approval of the listing application and the satisfaction of all applicable listing and regulatory requirements, as well as effectiveness of the registration statement. Field Trip will continue to maintain the listing of its Shares on the Toronto Stock Exchange under the symbol "FTRP"..

07:47 EDT Jacobs selected by Health Infrastructure for $582M redevelopment project - Jacobs was selected by Health Infrastructure to deliver architectural services for the New South Wales, or NSW, government's $582M, or AU$750M, Royal Prince Alfred Hospital Stage 1 Redevelopment project to redevelop and expand the existing facility to meet growing demand for healthcare services within the community. The RPA redevelopment will deliver a new hospital building and refurbishment of existing spaces, including more adult inpatient beds and expanded emergency department, intensive care unit, medical imaging services, operating theaters, and maternity, birthing and neonatal services. Jacobs' architects will deliver interior and exterior design and health planning services. The project is commencing one year earlier than originally planned, fast tracked by the NSW government as part of its COVID-19 Recovery Plan to create new jobs, improve resilience and build a future-proof economy.

07:44 EDT Summit Bank selects nCino Bank Operating System - nCino announced that $761M-asset, Oregon-based Summit Bank selected nCino's Bank Operating System to transform its operations and digitize its commercial lending business. Summit Bank will be utilizing nCino's Commercial Banking and Automated Spreading solutions to "empower the bank to gain insights faster and make proactive, impactful decisions that best serve its client base. nCino's Automated Spreading, powered by nCino IQ, can seamlessly spread financials to accurately and efficiently automate tasks and provide a greater opportunity for Summit to grow its financial portfolio," the company said.

07:41 EDT Jowell Global signs cooperation agreement for COCOVEL brand with Shanghai Gesber - Jowell Global announced that it has signed a strategic cooperation agreement with Shanghai Gesber Group on the latter's fragrance personal care product brand COCOVEL to jointly seek business growth in domestic and international household product markets. A signing ceremony was held on June 5 with Xuyou Sun, President of Gesber and Zhiwei Xu, CEO and chairman of the company attending the ceremony.

07:36 EDT Kiniksa reports defined regulatory pathway for Phase 3 mavrilimumab development - Kiniksa Pharmaceuticals outlined next steps for the development of mavrilimumab, an investigational fully-human monoclonal antibody that blocks activity of granulocyte macrophage colony stimulating factor by binding specifically to the alpha subunit of the GM-CSF receptor. Interactions between Kiniksa and the U.S. Food and Drug Administration on mavrilimumab in COVID-19-related acute respiratory distress syndrome, giant cell arteritis, and rheumatoid arthritis resulted in a defined path for Phase 3 clinical development for each indication. Kiniksa believes development of mavrilimumab in COVID-19-related ARDS represents the fastest path to potential registration. Based upon data from the Phase 2 portion of the Phase 2/3 clinical trial of mavrilimumab in non-mechanically ventilated patients with COVID-19-related ARDS and discussions with the FDA, Kiniksa has adjusted the final sample size to appropriately power the Phase 3 portion of the clinical trial. The Phase 3 clinical trial will enroll a total of approximately 600 non-mechanically ventilated patients. The primary efficacy endpoint remains as the proportion of patients alive and free of mechanical ventilation at Day 29. The Phase 3 portion of the clinical trial has already enrolled over 400 patients. Kiniksa expects data from the Phase 3 portion of the clinical trial in the first quarter of 2022. Kiniksa is engaged with the FDA and other government agencies on pathways to accelerate access to mavrilimumab as a potential therapeutic option for COVID-19-related ARDS. Kiniksa completed an end-of-Phase 2 meeting for GCA with the FDA. Kiniksa received guidance that a single, well-controlled pivotal Phase 3 clinical trial in approximately 450 patients could be sufficient for registration. The FDA agreed with the proposed 150 mg and 100 mg subcutaneous bi-weekly dose levels versus placebo on top of a steroid taper and agreed with a 52-week exposure duration to support chronic use. Kiniksa completed a pre-IND meeting for RA with the FDA. Kiniksa received guidance that two well-controlled Phase 3 trials in 1,000-1,500 patients with at least one-year of exposure to mavrilimumab could be sufficient for registration in a broad RA population, such as patients with inadequate response to methotrexate and/or methotrexate naive patients. The FDA agreed with the proposed 150 mg and 100 mg SC bi-weekly dose levels versus placebo. Mavrilimumab was dosed at 150 mg and 100 mg SC bi-weekly in over 550 RA patients in Phase 2b clinical studies in Europe which achieved prospectively-defined primary endpoints of efficacy and safety. Kiniksa intends to provide additional updates on the development of mavrilimumab following data from the Phase 3 clinical trial in COVID-19-related ARDS. Kiniksa's resources are currently focused on the commercial launch of ARCALYST in recurrent pericarditis, the Phase 3 clinical trial of mavrilimumab in COVID-19-related ARDS, the Phase 2b clinical trial of vixarelimab in prurigo nodularis, and the planned Phase 2 clinical trial of KPL-404 in RA. The company continues to expect that its approximately $264M of cash, cash equivalents and short-term investments will fund its current operating plan into 2023.

07:36 EDT Incyte announces U.S. FDA has extended sNDA review - Incyte announced that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application sNDA for ruxolitinib (Jakafi for the treatment of adult and pediatric patients 12 years and older with steroid-refractory chronic graft-versus-host disease. The new Prescription Drug User Fee Act target action date is September 22. The FDA extended the PDUFA action date to allow time to review additional data submitted by Incyte in response to the FDA's information request. The submission of the additional information has been determined by the FDA to constitute a Major Amendment to the sNDA, resulting in an extension of the PDUFA goal date by three months. "We remain confident in the data from the REACH3 trial supporting or sNDA submission for ruxolitinib and look forward to continued dialogue with the FDA throughout the remainder of the review process," said Steven Stein M.D., Chief Medical Officer, Incyte. "We will work closely with the agency and are dedicated to bringing this innovative treatment to patients with steroid-refractory chronic GVHD who urgently need new treatment options." The sNDA was based on data from REACH3, a Phase 3 randomized, open-label, multicenter study comparing ruxolitinib with best available therapyin adult and pediatric patients 12 years and older with steroid-refractory chronic GVHD.

07:35 EDT InflaRx doses first patient in Phase II clinical trial of vilobelimab - InflaRx announced the enrollment of the first patient in an open-label, multicenter Phase II clinical study evaluating vilobelimab alone and in combination with pembrolizumab in patients with PD-1 or PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma. The Phase II clinical trial is expected to enroll approximately 70 patients at sites in Europe, the U.S. and elsewhere. The study will investigate two independent arms: vilobelimab alone and vilobelimab in combination with pembrolizumab. The main objectives of the trial are to assess the safety and antitumor activity of vilobelimab monotherapy and to determine the maximum tolerated or recommended dose, safety and antitumor activity in the combination arm. The C5a/C5aR pathway has been implied as a potential driver for tumorigenesis, metastases and avoidance of immune cell destruction, particularly in the context of cSCC.

07:33 EDT Brooklyn ImmunoTherapeutics appoints Kevin D'Amour as CSO - Brooklyn ImmunoTherapeutics announced the appointment of Kevin D'Amour, Ph.D. as its Chief Scientific Officer, or CSO. D'Amour joins Brooklyn from ViaCyte, a private, clinical stage company developing stem cell-based therapy for type 1 and insulin-dependent type 2 diabetes, where he most recently served as CSO.

07:31 EDT FMC receives EPS registration for fluindapyr fungicide - FMC received U.S. Environmental Protection Agency, or EPA, registration for fluindapyr, a novel broad-spectrum succinate dehydrogenase inhibitor, or SDHI, fungicide. Fluindapyr provides broad-spectrum activity against a wide range of destructive diseases in row and specialty crops, as well as turf. Upon the grant of these registrations, farmers around the world will have access to fluindapyr for preventative control of various fungal diseases in row crops, including multiple rust diseases in cereals and soybeans, as well as powdery mildew in specialty crops. Studies show fluindapyr controls pathogens that are resistant to other chemical classes.

07:28 EDT Medipharm, ADREXpharma extend supply agreement for five years - MediPharm Labs announced that it has extended its supply agreement with ADREXpharma. The Agreement was renewed for 5 years, to June 2026, with a mutual option to extend further. MediPharm supplies ADREX with THC and CBD cannabis products for sale and distribution in Germany to approximately 19,000 pharmacies that could provide access to cannabis products over time.

07:22 EDT BeyondSpring announces poster presentation of PROTECTIVE-2 phase 3 data - BeyondSpring announced a poster presentation of the company's lead asset plinabulin, a selective immunomodulating microtubule-binding agent, in combination with pegfilgrastim in breast cancer as part of the Phase 3 PROTECTIVE-2 chemotherapy-induced neutropenia study, at the Federation of Clinical Immunology Societies Annual Meeting being held from June 8-11, 2021. BeyondSpring's poster is titled "Adding Plinabulin to Pegfilgrastim Reverses the Immune Suppressive Potential of Peg while Offering Superior Prevention of Chemotherapy Induced Neutropenia versus Peg Alone." Plinabulin in combination with pegfilgrastim demonstrated a superior immune profile and CIN prevention outcomes for patients treated with plinabulin in combination with pegfilgrastim compared to pegfilgrastim alone in breast cancer patients dosed with TAC in PROTECTIVE-2 Phase 3 study. Compared to pegfilgrastim alone, the plinabulin and pegfilgrastim combination showed decreased production of immature neutrophil band, and decreased promyelocytes and myelocyte production (p=0.0488). Immature neutrophil band and promyelocytes and myelocytes are less functional defending against infection and have potentially deleterious immune suppression effects. The company has submitted New Drug Applications for plinabulin in combination with pegfilgrastim as a treatment for the prevention of CIN for review in both the U.S. and China. The U.S. FDA accepted the NDA with Priority Review and assigned a Prescription Drug User Fee Act action date of November 30, 2021.

07:20 EDT Calibre Mining announces update on 2021 drilling program - Calibre Mining is pleased to provide an update on the Company's 80,000 metre, 2021 drilling program, highlighting results of exploration and resource expansion drilling at the Company's Libertad concessions. Highlights: Volcan Vein: 11.37 g/t Au over 5.4 metres ETW from 61.4 metres; 9.26 g/t Au over 1.7 metres ETW from 76.9 metres; 2.37 g/t Au over 6.2 metres ETW from 67.2 metres. Tranca Vein: 16.78 g/t Au over 2.8 metres ETW from 41.9 metres; 13.83 g/t Au over 4.4 metres ETW from 127.7 metres; 3.27 g/t Au over 4.1 metres ETW from 107.1 metres. 2021 Calibre Drill Program: 16 drill rigs currently active on Calibre's 100% owned properties; Calibre is guiding 170,000 - 180,000 ounces of gold production for the year, generating strong cash flows to self-fund new growth opportunities and an extensive 80,000 metre exploration and infill drilling program The Volcan vein system is located approximately four kilometres south of the Libertad mill. Previous exploration drilling completed in 2012 and 2017 testing the upper 100 metres in two areas along the system returned multiple high-grade intercepts including 9.69 g/t Au over 10.7 metres ETW from 49 metres in hole VN-17-009; 10.56 g/t Au over 4.5 metres ETW from 41.2 meters in holes VN-17-013; and 5.78 g/t Au over 4.1 metres from 111.2 metres in hole VN-17-021. Initial results received from this year's drilling program have confirmed the presence of near surface gold mineralization along the Volcan trend which remains open along strike and at depth. The Company plans to continue drilling at Volcan with a second campaign of step-out exploration holes drilled along strike to test the continuity of mineralization between the two zones and the potential for high-grade mineralization to extend at depth. The Tranca vein system is located approximately 9 kilometres east of the Libertad mill and 500 metres south of the Jabali underground mine currently in operation. Since early 2020, Calibre has been drilling along a 1.5 kilometre section of the Tranca trend which has been traced for another 2.5 kilometres along strike to the east. Along strike to the west, the Tranca system extends into the Nancite prospect where multiple veins occur. The Company continues to be encouraged by the continuity of gold grades and potential for higher grade shoots along the zone and plans to accelerate exploration drilling with a second drill during the coming weeks. Rosario Vein: 3.67 g/t Au over 8.0 metres ETW from 99.1 metres; 2.34 g/t Au over 7.3 metres ETW from 130.8 metres; 3.13 g/t Au over 4.0 metres ETW from 112.8 metres; 4.02 g/t Au over 2.4 metres ETW from 69.8 metres. Jabali Vein: 5.45 g/t Au over 3.3 metres ETW from 30.4 metres; 51.90 g/t Au over 0.8 metres ETW from 44.6 metres. While we have focused largely on exploration drilling this year, we are likewise pleased with the results of resource expansion and infill drilling at the Rosario deposit where we continue to see opportunities to expand open pit mineral resources located within a short trucking distance of the Libertad mill. At Jabali, results of a final infill drilling campaign will be integrated into the mineral resource estimate in support of future underground mine planning. At Pavon, Calibre completed condemnation drilling and continues to explore along strike and down plunge of the Pavon Central and Norte veins including at the recently identified Candida vein splay extending from the main Pavon Norte deposit. Currently, the Company has two rigs operating at Pavon and will continue step out exploration drilling along strike and down dip of the principal vein systems.

07:17 EDT Qiwi appoints Andrey Protopopov as Chief Executive Officer - QIWI announced the appointment of Andrey Protopopov as Chief Executive Officer effective June 2, 2021. As CEO, Protopopov will take over the responsibilities of Boris Kim. Prior to his current position as the CEO of Payment Services Segment, Protopopov has served as Head of IT and Product from June 2015 to August 2019 and Head of Product Management from September 2013 to June 2015.

07:16 EDT Mammoth Energy releases information regarding work in Puerto Rico - Mammoth Energy Services announced that it has posted to its website additional information addressing two documents recently released by the Federal Emergency Management Agency that relate to hurricane repair work performed by Cobra Acquisitions in Puerto Rico. FEMA released a Determination Memorandum dated May 26, 2021, related to the first of two contracts Cobra successfully performed for the Puerto Rico Electric Power Authority. Cobra and PREPA executed the Emergency Master Service Agreement for PREPA's Electrical Grid Repairs - Hurricane Maria on October 19, 2017. PREPA has 60 days from the receipt of FEMA's Determination Memorandum to file an appeal. In addition to the Determination Memorandum, the Company also recently obtained a draft Cost Analysis prepared by FEMA in response to the recommendation of the Department of Homeland Security's Office of Inspector General made in an OIG report dated July 3, 2019. The OIG recommended that FEMA conduct a comprehensive analysis of Cobra's Contract costs and disallow reimbursement to PREPA of any Cobra Contract costs that are not reasonable. In order to address the OIG recommendation, FEMA and the United States Army Corps of Engineering analyzed the reasonableness of the actual Cobra costs for which PREPA is seeking reimbursement from FEMA. The scope of FEMA's Cost Analysis included the following: Evaluate Cobra's overall level of effort and work productivity based on the statement of work developed by FEMA; Compare Cobra's actual costs to those of other electrical contractors that performed similar work when the data existed. FEMA reviewed Cobra's cost of work performed per transmission line and distribution line, Cobra's overall actual average daily rate, and the daily per diem to cover lodging and living expenses; and Reviewed USACE's report and consider its recommendations prior to making a conclusion on cost reasonableness. After completing its Cost Analysis, FEMA came to the conclusions below in the draft report. Page 13 - Cobra's overall average rate is lower than all other contractors reviewed. Page 14 - Given the condition and circumstances on the island, the evaluation of all data available to assess the level of effort for the work performed, and the comparison to other contract costs, FEMA found that Cobra's costs per tower for both transmission and distribution lines for the work captured on this project appear reasonable. Page 15 - Cobra's duration of work for electrical work appears to be reasonable. Page 19 - Cobra's overall average rate is lower than all other contractors reviewed. If the average 9% tax markup is added, the rates fall in line with the MOUs and are still lower than Whitefish rates. Page 20 - Based on the results of the FEMA and USACE analyses, FEMA has no reason to believe that the cost of the work performed by Cobra is not reasonable. FEMA's Determination Memorandum and Cost Analysis raised two contract compliance issues. Excess Man Count- FEMA identified 43 days when Cobra exceeded the highest allowable staffing level agreed to in Exhibit 1-B Contractors' Rate Schedule of 882 personnel without the written consent of PREPA. FEMA identified $24,439,810.49 related to this issue. At the request of Puerto Rico and the full knowledge and consent of PREPA and FEMA, Cobra agreed to bring on a subcontractor that had previously worked for USACE and already had both personnel and equipment in Puerto Rico. The addition of these personnel was in full compliance with the Contract. Mobilization Expenses- FEMA identified that Cobra began billing for the daily minimum amount due of $1,563,000, based on 250 linemen, starting on October 25, 2017; however, Cobra did not reach the required minimum number of linemen on the island until November 12, 2017. As a result, FEMA determined that $21,451,272.51 was ineligible. Further, FEMA determined that $133,800 in lodging rentals were ineligible. FEMA cited Section 4.3 of the Contract that "payment will be made for actual days worked". The Contract provided that Cobra would be paid a daily minimum amount of $1,563,000. Cobra began billing the daily minimum on October 25, 2017, after Cobra supplied PREPA with a roster of 250 linemen that it was mobilizing to the island. Cobra incurred $133,800 in lodging for the Management Team for Operations and Safety personnel included in Exhibit B of the Contract. These personnel were housed in San Juan to be closer to PREPA's offices and allow the Management Team to be more accessible to PREPA for regular meetings. The charges were invoiced to PREPA at cost. These costs were necessary to Cobra's performance and are reimbursable under the Contract. FEMA's citation of Section 4.3 in regards to mobilization expenses is a mischaracterization of the contractual terms. Section 4.3 relates to the termination of work, not the mobilization of lineman.

07:14 EDT Fastly: Global network coming back online - Fastly said via Twitter: "We identified a service configuration that triggered disruptions across our POPs globally and have disabled that configuration. Our global network is coming back online." Reference Link

07:12 EDT Compugen presents updated data from Phase 1 study of COM701 - Compugen presented updated data from its Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo, or nivolumab, in an oral presentation at the ASCO 2021 Annual Meeting, being held virtually on June 4-8, 2021. COM701 is a first-in-class investigational therapeutic antibody targeting PVRIG, a novel immune checkpoint discovered computationally by Compugen. "These new data from our COM701 clinical program are meaningful for two key reasons," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. "First, durability data show multiple patients on treatment beyond one year, strengthening our confidence that PVRIG blockade through COM701 may provide meaningful clinical benefit in tumor types typically unresponsive to immune checkpoint inhibitors, including in patients with prior progression on these treatments. Our ongoing confirmed complete response from the combination arm is particularly noteworthy given it was achieved in a patient with anal squamous cell carcinoma with prior progression on Opdivo and is on study treatment now out to 22 months. We believe these results support our hypothesis that dual blockade of PVRIG and PD-1 may be key to driving immune responses in certain patient populations."

07:11 EDT Summit Therapeutics set to join Russell 3000 Index - Summit Therapeutics is set to join the broad-market Russell 3000 Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US markets open on June 28, according to a preliminary list of additions posted by FTSE Russell.

07:10 EDT Jushi's Franklin Bioscience to open 20th BEYOND/HELLO location - Jushi Holdings announced its subsidiary, Franklin Bioscience - NE LLC, will open the Company's 13th BEYOND / HELLO medical marijuana dispensary in Pennsylvania and the Company's 20th BEYOND / HELLO dispensary nationwide. On Friday, June 11, 2021 at 10:00 a.m., BEYOND / HELLO Easton will begin serving Pennsylvania medical marijuana patients and caregivers, providing an unmatched in-store experience, coupled with convenient online reservations available through beyond-hello.com and in-store express pick-up.

07:09 EDT Poet Technologies announces availability of samples of CWDM4 Optical Engines - POET Technologies announces that samples of its 100G and 200G CWDM4 Optical Engines will be available beginning in early July. Powered by four flip-chipped 28G and 28G PAM4 CWDM DFB lasers, the POET Optical Engines include an integrated athermal multiplexer and demultiplexer, 28G detectors, monitor photodiodes and bonding pads. Operating to MSA standards for the QSFP28 module, the POET Optical Engines will be available in chip sets for transmit only, receive only or in a combination transmit and receive single multi-chip engine less than 60mm square. POET will also soon be offering 400G DR4 and FR4 transmit and receive optical engines. Samples of the receive optical engine will be available in September. Samples of the transmit engine, based upon high power CW lasers and silicon photonic modulators, will be available beginning in Q4 2021.

07:07 EDT Amicus says UK's MHRA grants early access to AT-GAA - Amicus Therapeutics announced that the UK's Medicines and Healthcare Products Regulatory Agency has granted a positive scientific opinion through the Early Access to Medicines Scheme of AT-GAA, the Company's investigational two-component therapy for the treatment of Pompe disease. This positive opinion means that eligible adults living with late-onset Pompe disease who have received alglucosidase alfa for at least 2 years can now switch and have access to AT-GAA prior to marketing authorization in the UK. The MHRA's decision is based on the evaluation of the effects of AT-GAA in LOPD patients and its safety profile, including data from both the Phase 1/2 and Phase 3 PROPEL study. Marketing Authorization Applications for AT-GAA are expected to be submitted with the UK and EU, respectively, in the second half of 2021. For the full approval in the UK, Amicus will seek inclusion of the treatment population to all ERT-switch patients regardless of length of time on prior ERT, as well as the treatment naive population. Future studies will also investigate the treatment of patients with Infantile Onset Pompe Disease. Previously, the MHRA has granted the PIM designation to AT-GAA. Also, the U.S. FDA granted Breakthrough Therapy Designation to AT-GAA for the treatment of LOPD based on clinical efficacy results from the Phase 1/2 clinical study. A rolling Biologics License Application for AT-GAA was initiated with the U.S. FDA in the fourth quarter of 2020 and is on track with submission of the final modules in the second quarter of 2021.

07:06 EDT Southwest to increase its 2022 firm orders by 34 Boeing 737 MAX 7 aircraft - In a regulatory filing, Southwest (LUV) said: "Based on improving revenue trends and ongoing fleet modernization plans, the company recently entered into a Supplemental Agreement with The Boeing Company to increase its 2022 firm orders by 34 Boeing 737 MAX 7 aircraft, consisting of two 2022 options exercised and 32 options accelerated and exercised from later years, resulting in 234 firm orders for MAX 7 aircraft. Additionally, the company accelerated 32 options into 2023, 16 options into 2024, 16 options into 2025, and added 32 new options into 2026 through 2027, bringing the total firm and option order book to 660 aircraft. The company continues to estimate its 2021 total capital expenditures to be approximately $500M, with minimal aircraft capital spending, and now expects its contractual aircraft capital spending to be approximately $1.5B in 2022, compared with its previous guidance of approximately $700M. Fleet and capacity plans will continue to evolve as the company manages through this recovery period, and it will continue to evaluate its remaining 40 MAX options in 2022. The company continues to plan to retire 30 to 35 of its Boeing 737-700 aircraft annually, on average, over the next 10 to 15 years; however, with its cost-effective order book, the company retains significant flexibility to manage its fleet size, including opportunities to accelerate fleet modernization efforts if growth opportunities do not materialize."

07:05 EDT Anavex announces exceeding of enrollment target for ANAVEX 2-73 phase 2b/3 trial - Anavex Life Sciences announced that it has exceeded its enrollment target for the ANAVEX 2-73 Phase 2b/3 study in Alzheimer's disease. The company expects to announce topline results from this study by mid-2022. The study includes a prespecified precision medicine biomarker, SIGMAR1 gene expression, which demonstrated correlation with direct measures of clinical benefit, cognition and activities of daily living and function in a previous Phase 2a Alzheimer's disease study. The double-blind, placebo-controlled 450-patient Phase 2b/3 ANAVEX 2-73 clinical study in patients with Alzheimer's disease exceeded enrollment beyond 450 patients at 52 sites across North America, Europe and Australia using ADAS-Cog and ADCS-ADL as primary endpoints. This clinical trial is measuring efficacy, tolerability, and safety of two different once daily oral ANAVEX 2-73 doses or placebo. ANAVEX 2-73 is an orally available, small-molecule activator of the sigma-1 receptor. Data suggests that activation of SIGMAR1 results in the restoration of complete housekeeping function within the body and is pivotal to restoring neural cell homeostasis and promoting neuroplasticity. PET scan data previously confirmed dose-dependent target engagement of SIGMAR1 with ANAVEX 2-73.

07:04 EDT Rockwell Medical, Drogsan Pharmaceuticals enter license agreement for Triferic - Rockwell Medical and Drogsan Pharmaceuticals announced that the Companies entered into an exclusive license agreement for the rights to commercialize Triferic AVNU in Turkey. Under the terms of the license agreement, Drogsan will be the exclusive development and commercialization partner for Triferic in Turkey and Rockwell Medical will supply the product to Drogsan. The agreement also allows for Drogsan to negotiate further geographic expansion into the surrounding region. In consideration for the license, Rockwell Medical will receive an upfront fee and will be eligible for milestone payments based on reimbursement price approval.

07:02 EDT CareDx acquires Transplant Hero, terms not disclosed - CareDx announced it has acquired Transplant Hero LLC, a New York-based provider of a mobile application supporting the needs of transplant patients. The company said, " The acquisition of Transplant Hero builds on AlloCare, the comprehensive CareDx mobile health app for managing the day-to-day health of patients before and after transplant. Transplant Hero strengthens CareDx's focus on the transplant patient journey and adds to its growing digital portfolio which includes a robust suite of cloud-based solutions and software for transplant centers and dialysis providers." Transplant Hero provides a smartphone app focused on helping transplant patients manage their medications through alarms and interactive logging of medication events. Medication management is especially important for transplant patients who must follow a regular regimen to protect against organ rejection. The number of pills and the complexity of the regimen often makes medication management a challenge. The app offers support to various types of organ recipients, including kidney, heart, lung, liver, pancreas, and small bowel.

07:01 EDT Palantir awarded $7.4M contract renewal with U.S. Centers for CDC - Palantir Technologies announced it was awarded a $7.4M one-year contract renewal with the U.S. Centers for Disease Control and Prevention, or CDC, to continue to provide an outbreak response and disease surveillance solution for the Data Collation and Integration for Public Health Event Response, or DCIPHER, Program. DCIPHER is designed to assist public health experts in routine disease surveillance and outbreak management for real-time events.

06:58 EDT Becton Dickinson receives orders for 2B injection devices for vaccination effort - Becton Dickinson announced that it has received pandemic orders for needles and syringes totaling 2B injection devices to support global COVID-19 vaccination efforts. This new milestone reflects commitments to governments across the world, including the United States, Australia, Brazil, Canada, France, Germany, India, Philippines, Saudi Arabia, South Africa, Spain and the United Kingdom, among many others, as well as non-governmental organizations supporting vaccine deployment for developing countries. In total, BD is supporting pandemic orders for more than 40 countries, non-governmental organizations and other partners. BD has delivered more than 900M injection devices around the world to date, with the remaining orders to be delivered between now and the end of 2022 to support vaccine administration.

06:54 EDT Hyatt raises 2021 net rooms growth guidance to 6% from greater than 5% - Hyatt Hotels announced an increase to its 2021 net rooms growth outlook and the completion of two transactions as part of its ongoing capital strategy. Details are as follows: On June 4 a Hyatt affiliate and Service Properties Trust, or SVC, reached an agreement with respect to 22 Hyatt Place hotels in the U.S. owned by subsidiaries of SVC. Under the terms of the amended agreement effective April 1 Hyatt will continue to manage 17 of the 22 Hyatt Place hotels owned by subsidiaries of SVC for a 10-year term. As a result of the amended agreement, Hyatt is increasing its net rooms growth outlook for 2021 to approximately 6.0%, up from the prior expectation of greater than 5.0%. On June 4 a Hyatt affiliate sold the 490-room Hyatt Regency Lost Pines Resort and Spa near Austin, Texas for approximately $275M to an unrelated third party and entered into a long-term management agreement for the property upon sale. The owner anticipates enhancing and expanding this unique resort destination located on 405 acres along the banks of the Colorado River. On June 3 a Hyatt affiliate acquired the 59-room Ventana Big Sur, an Alila Resort, located in Big Sur, California for approximately $148M, securing the Company's long-term brand presence in a highly sought-after resort destination. The resort, situated on 162 acres in one of the world's premier leisure destinations, also includes 63 distinctive camping areas and 15 tent cabins and is one of three world-class Alila resorts operating in California. With the completion of both asset transactions at attractive values, Hyatt remains on track to realize net proceeds from the sale of real estate of approximately $1.5B by March 2022 as part of its capital strategy announced in March 2019. To date, and including the net proceeds from the aforementioned transactions, the Company has realized approximately $1.1B in net proceeds while continuing to expand its management and franchising business. In addition to reducing the earnings from owned and leased hotels, Hyatt has expanded its managed and franchised property base by approximately 150 hotels, or by 18%, from March 2019 to May 2021 that will drive an increased percentage of earnings coming from management and franchising activity.

06:49 EDT Fastly: Issue has been identified, fix being implemented - Reference Link

06:46 EDT Roche obtains CE mark for the SARS-CoV-2 Antigen Self Test Nasal - Roche announced it has received CE mark for its SARS-CoV-2 Antigen Self Test Nasal for at-home testing. The test will be available in countries accepting the CE mark through pharmacies and other locations, in packs of five tests. "An early version of the test has already been available as a home-test in a number of European markets under local special approval pathways since February 2021. With the CE Mark, the SARS-CoV-2 Antigen Self Test Nasal for rapid self testing of COVID-19 test has received official approval following the traditional registration pathway and can now also be used in markets that have not established regulatory exemption pathways. By following simple instructions, individuals can perform the test at home using a nasal swab without special training or the supervision of a healthcare worker. The test provides results in as little as 15 minutes and can help people to conveniently check if they are likely to be infectious from the comfort of their home. In the case of children under 18 years of age, the test must be performed by an adult or under close adult supervision... Complementary to the SARS-CoV-2 Antigen Self Test Nasal, Roche is offering NAVIFY Pass. This digital solution allows individuals and healthcare professionals to remotely store, display, and share their COVID-19 test results and vaccine status through a personalised QR code. Having easy digital access to test results and vaccination status could potentially be used by both individuals and companies to facilitate access to locations with COVID-19 entry protocols, such as restaurants or entertainment venues, as well as to validate safety to travel," the company said.

06:36 EDT Thor Industries says it expects long-term health in the RV industry - "We continue to see robust demand for our RVs and see no signs of demand slowing even as the economy recovers from the pandemic. The most recent RVIA forecast projects total North American wholesale RV shipments of approximately 576,100 units in calendar year 2021, representing an increase of 33.8% over 2020. We are focused on strategically increasing capacity and maximizing production efficiencies to fulfill the growing demand from our dealers. Ultimately, however, the number of THOR Industries units shipped in both fiscal and calendar 2021 depends on our ability to manage through the ongoing global supply chain issues. We have numerous team members throughout the organization focused on resolving near-term supply chain shortages while also pursuing long-term solutions to avoid potential future issues," said Martin. "This is the first quarter in which Tiffin Group was fully included in our quarterly results, and I'd like to say that we are very pleased with the acquisition and with the Tiffin Team. The integration is going as planned, and we see a bright future for our combined companies. Looking ahead, we expect long-term health in the RV industry. We see the increased interest in the outdoors and RV lifestyle as a fundamental shift in consumer preferences, a shift that began before the pandemic and picked up steam over the last year. It is a trend we believe will continue to grow throughout our global marketspace. As one example of the underlying data supporting our optimism, we are seeing growth in two areas that have historically been frequent paths-to-purchase for the first-time RV buyer; outdoor camping and RV rentals. In its recently released 2021 annual camping report, Kampgrounds of America ("KOA") estimated that there were more than 10 million new households camping in calendar 2020 and estimated that an additional 4.3 million people will try camping in 2021 for the first time. KOA also projects that there will be 52.6 million camping households in 2021. In addition to new campers, the industry saw a sizeable increase in the number of RV rentals in 2020. The findings of THOR Industries 2020 RV Rental Study support the belief that those who rent an RV have a high propensity to eventually purchase an RV. These indicators, when combined with our robust order backlog and the historical 3 to 5-year trade-in cycle of current RV owners, reaffirm our belief that strong demand for THOR Industries products is sustainable over the coming months and years," concluded Martin.

06:33 EDT Cathie Wood's ARK Investment bought 40.5K shares of Trimble on Monday

06:32 EDT Hexo commits to offset operational carbon emissions - HEXO announced a commitment to offsetting the Company's operational carbon emissions and the personal emissions of all 1,200 employees, making HEXO 100% carbon neutral from September 2021 onwards. The Company is also committing to offset the plastic used in their pouch packaging through Plastic Bank in partnership with Dymapak, HEXO's primary packaging supplier. These concrete actions highlight the Company's early steps towards a long-term commitment to leading the cannabis industry on Environmental, Social, and Governance, or ESG, action. Through a partnership with Offsetters, in support of the Great Bear Forest Project, HEXO will be measuring and offsetting the Company's corporate carbon emissions starting with its 2020 calendar year, making HEXO 100% carbon neutral by September 2021, as well as offsetting their employees' personal emissions.

06:16 EDT Kroger's Family of Companies plans to hire 10,000 associates - The Kroger Co. yesterday announced its Family of Companies' first nationwide hybrid hiring event, including virtual and in-store interviews, will take place on Thursday, June 10. The goal of the event is to hire 10,000 associates supporting retail, e-commerce, pharmacy, manufacturing, and logistics operations.

06:06 EDT Global Net Lease collects 100% of rent for April, May - Global Net Lease announced that it collected 100% of the original cash rent due for the months of April and May, as of June 7. The company also announced that in Q1 and Q2 to date it had closed on or had in its forward acquisition pipeline eight properties for approximately $270M.

06:04 EDT PDS Biotechnology presents interim data from Phase 2 trial on PDS0101 - PDS Biotechnology announced the presentation of interim data from the Phase 2 trial led by the National Cancer Institute, or NCI, of the National Institutes of Health, or NIH, at the American Society of Clinical Oncology 2021 Annual Meeting. The Phase 2 trial studies PDS0101, or Versamune-HPV16, in combination with two investigational immune-modulating agents: bintrafusp alfa, or M7824, a bifunctional "trap" fusion protein targeting TGF-beta and PD-L1, and NHS-IL12, or M9241, a tumor-targeting immunocytokine. PDS0101 is an immunotherapy candidate designed to treat cancers caused by infection with HPV16, or HPV16-positive cancers, by activating the immune system to produce in vivo CD8+ T-cells to target and kill tumors that are HPV16-positive. Analyses of immune responses and other immune correlates are ongoing. The presentation includes data from a total of 25 patients with data available as of the time of presentation submission, an update on the data previously reported for the original fourteen HPV16-positive patients who were in the subject of the abstract published on May 19th; an additional seven HPV16-negative patients who were not discussed in the abstract, and an additional four HPV16-positive patients who are checkpoint inhibitor refractory whose data became available after the abstract submission.

05:37 EDT BlackBerry announces QNX Neutrino RTOS adopted in new LCD cluster - BlackBerry announced that its QNX Neutrino Realtime Operating System, or RTOS, has been adopted in a new digital LCD cluster jointly developed with BiTECH Automotive. The digital instrument cluster is being installed in Changan Automobile's new SUV, the UNI-K, which has entered mass production, providing a personalized user experience for drivers while ensuring the SUV's critical systems. The Changan UNI-K is a new SUV which features a smart driving assistance program and a smart cockpit with an interactive monitoring system, or IMS.

05:28 EDT ArcelorMittal makes $10M investment in Heliogen - ArcelorMittal announced the completion of its first XCarb innovation fund investment since launching the initiative in March. The company has invested an initial $10M in Heliogen, a renewable energy technology company which focuses on "unlocking the power of sunlight to replace fossil fuels." Heliogen's technology will harness solar energy by using a field of mirrors which will act as a multi-acre magnifying glass to concentrate and capture sunlight. The sunlight will then be subsequently converted into heat, electricity or clean fuels. The Heliogen technology will also be capable of creating 100% green hydrogen, which Heliogen is working to develop as its first HelioFuel. Hydrogen sits at the heart of ArcelorMittal's Innovative-DRI technology pathway, which involves using hydrogen instead of natural gas as the reductant in the production of direct reduced iron. In addition to the $10M investment, ArcelorMittal and Heliogen have signed a memorandum of understanding which aims to evaluate the potential of Heliogen's products in several of ArcelorMittal's steel plants.

05:21 EDT Talos Energy forms joint venture with Storegga for CCS project opportunities - Talos Energy announced that it has formed an exclusive joint venture with Storegga to source, evaluate and develop carbon capture and storage, or CCS, project opportunities on the United States Gulf Coast and Gulf of Mexico, or GOM, including state and federal waters offshore Texas, Louisiana, Mississippi and Alabama. The Partners are actively exploring opportunities with counterparties along the CCS value chain. operational and sub-surface expertise with Storegga's leading end-to-end CCS project experience. Under the terms of the agreement, as individual CCS projects are matured in the future, each will be ring-fenced with separate operating agreements, financing structures and the possibility of additional working interest partners. The agreement requires zero up front capital commitments, and the partnership will share costs 50/50 in the initial phases. Talos is designated as the operating partner of the joint venture. Storegga is a European leader in CCS as a lead developer of the Acorn CCS and Acorn Hydrogen Projects and also is actively developing a cutting edge direct carbon air capture, or DAC, project. The Acorn project is the most advanced large-scale CCS project in the United Kingdom with final investment decision, or FID, expected in 2022.

05:04 EDT Hyatt opens 7Pines Resort Ibiza - Hyatt announced the opening of 7Pines Resort Ibiza, part of Destination by Hyatt hotel. The 185-all-suite luxury clifftop resort welcomes guests to the White Island and offers amenities.